Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
$0.05
N/A-2.8213,560 shs1,253 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.82
+0.3%
$0.82
$0.70
$1.65
$63.33M2.05360,639 shs116,706 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$2.17
+11.9%
$1.56
$0.63
$2.75
$116.01M0.96960,207 shs2.24 million shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.71
-3.2%
$0.85
$0.66
$2.29
$27.62M1.57161,345 shs120,823 shs
Exicure, Inc. stock logo
XCUR
Exicure
$6.47
-4.6%
$9.24
$1.44
$36.00
$40.88M3.57577,968 shs34,169 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%-95.00%-90.00%-99.00%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%+6.75%+4.51%-2.76%-35.78%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
0.00%+3.98%+11.79%+183.54%+45.41%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00%+5.74%-20.37%-9.60%-60.91%
Exicure, Inc. stock logo
XCUR
Exicure
0.00%+9.17%-40.46%-48.46%+2,034.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
1.4044 of 5 stars
3.53.00.00.00.60.00.0
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.2607 of 5 stars
3.25.00.00.00.02.50.0
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.2625 of 5 stars
0.03.00.00.00.00.80.6
Exicure, Inc. stock logo
XCUR
Exicure
1.5756 of 5 stars
0.05.00.04.71.30.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3.00
Buy$4.75482.82% Upside
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.40
Hold$7.00222.58% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MIST, XCUR, CLSD, CALA, and SCYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$5.00
5/23/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $5.00
5/16/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
5/15/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$4.00 ➝ $3.00
4/8/2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$1.66M38.15N/AN/A($0.51) per share-1.60
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1M116.01N/AN/A$0.25 per share8.68
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.75M7.36N/AN/A$1.45 per share0.49
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/A$1.12 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$0.41N/AN/AN/A-818.57%N/A-114.23%8/11/2025 (Estimated)
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$41.52M-$0.78N/AN/AN/AN/A-329.85%-67.20%8/6/2025 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.56N/A14.16N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)
Exicure, Inc. stock logo
XCUR
Exicure
-$9.70M-$3.82N/AN/AN/A-219.60%-82.03%8/11/2025 (Estimated)

Latest MIST, XCUR, CLSD, CALA, and SCYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/27/2025Q1 2025
Exicure, Inc. stock logo
XCUR
Exicure
N/A-$0.45N/A$0.49N/AN/A
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
5/14/2025Q1 2025
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 million
5/14/2025Q1 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.19-$0.31-$0.12-$0.31N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
Exicure, Inc. stock logo
XCUR
Exicure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.19
3.19
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
4.06
4.67
4.67
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.83
5.83
Exicure, Inc. stock logo
XCUR
Exicure
N/A
2.91
2.91

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
86.18%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%
Exicure, Inc. stock logo
XCUR
Exicure
42.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3077.71 million72.89 millionOptionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3053.46 million43.04 millionOptionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million37.12 millionOptionable
Exicure, Inc. stock logo
XCUR
Exicure
506.32 million5.79 millionNot Optionable

Recent News About These Companies

Exicure Shares Up After Swing to Profit in 1Q
Why Exicure Inc. (XCUR) Soared on Monday
Exicure announces issuance of new patent in Australia
Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm
Exicure announces purchase agreement with GPCR Therapeutics

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

$0.0001 0.00 (0.00%)
As of 12:25 PM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

$0.82 +0.00 (+0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$0.82 +0.01 (+1.23%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Milestone Pharmaceuticals stock logo

Milestone Pharmaceuticals NASDAQ:MIST

$2.17 +0.23 (+11.86%)
Closing price 04:00 PM Eastern
Extended Trading
$2.18 +0.01 (+0.46%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.71 -0.02 (-3.23%)
As of 04:00 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Exicure stock logo

Exicure NASDAQ:XCUR

$6.47 -0.31 (-4.57%)
Closing price 04:00 PM Eastern
Extended Trading
$6.32 -0.15 (-2.32%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.